Automated monitoring of SEC filings, FDA approvals, clinical trials, regulatory decisions, and conference disclosures - scored for significance and filtered to surface only what matters. A StrategyLand product.
Purpose-built to surface only the healthcare events that are reasonably expected to materially affect share prices. Complements the StrategyLand Stock Screener for complete equity analysis.
Every event is scored against 50+ healthcare-specific keywords with weighted positive, negative, and neutral signals. Only "Very Significant" events surface.
Aggregates data from 10+ sources including SEC EDGAR, FDA, EMA, MHRA, ClinicalTrials.gov, NIH/NCI, and major medical conferences.
Track healthcare events across US (SEC/FDA), UK (RNS/MHRA), China (HKEX), and Europe (EMA) - all from a single dashboard with market-specific tabs.
Get alerted to critical events via email and in-dashboard notifications. Never miss an FDA approval, Phase 3 result, or significant regulatory filing.
Three automated steps that run every 12 hours, so you can focus on decisions instead of data collection.
Automated scripts pull data from SEC EDGAR, FDA, ClinicalTrials.gov, EMA, MHRA, NIH/NCI, ASCO, ESMO, ASH, RNS, and HKEX every 12 hours.
Each event is analyzed against 50+ healthcare keywords, assigned a significance score, classified by sentiment, and deduplicated across sources.
Only events scoring above significance thresholds appear in the dashboard. Filter by market, source, ticker, or date range to find what matters to you.
We monitor the primary regulatory and disclosure channels that move healthcare stock prices.
Form 8-K current reports from healthcare companies in major ETFs (IBB, XBI) - material events, acquisitions, and executive changes.
New drug approvals, supplemental applications, priority reviews, and breakthrough therapy designations from the openFDA API.
Phase 2/3 trial results, primary endpoint completions, and new registrations for compounds from tracked companies.
European Medicines Agency marketing authorizations, CHMP opinions, and safety referrals for the EU market.
UK Medicines and Healthcare products Regulatory Agency approvals and safety communications via GOV.UK.
National Institutes of Health and National Cancer Institute press releases covering breakthrough research and grant-funded trial results.
ASCO, ESMO, ASH, AACR, and AHA - late-breaking abstracts and plenary session disclosures that move markets.
London Stock Exchange Regulatory News Service announcements from UK-listed healthcare and biotech companies.
Hong Kong Exchange announcements from major Chinese biotech and pharmaceutical companies listed on the main board.
Healthcare is global. Track regulatory events and filings across the world's largest equity markets - the same markets covered by StrategyLand's multi-market screener.
8-K filings from IBB/XBI constituents, FDA drug approvals, clinical trial milestones, and NIH press releases.
Regulatory News Service announcements from LSE-listed healthcare companies and MHRA regulatory decisions.
Hong Kong Exchange announcements from major Chinese biotech and pharmaceutical companies on the main board.
European Medicines Agency marketing authorizations, committee opinions, and regulatory updates across the EU.
Each event is scored against 50+ healthcare-specific keywords including "FDA approval", "Phase 3 results", "breakthrough therapy", "pivotal study", and more. Events must exceed a significance threshold (50 for critical, 35 for important) to appear in the dashboard. This filters out routine filings and surfaces only events that are reasonably expected to affect share prices.
The monitor runs automatically every 12 hours, pulling fresh data from all 10+ sources. A 12-hour guard prevents duplicate runs. Historical events are retained for 90 days before being archived.
The monitor tracks companies in major healthcare indices and ETFs including the iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and equivalent UK and China healthcare constituents. This covers the largest and most actively traded healthcare and biotech stocks globally.
Yes. The dashboard automatically submits critical events via Netlify Forms, which can be configured to send email notifications to specified addresses. You can also use the in-dashboard notification bell to track new events since your last visit.
We pull from SEC EDGAR (8-K filings), FDA (openFDA API), ClinicalTrials.gov (API v2), EMA (ema.europa.eu), MHRA (GOV.UK API), NIH/NCI press releases, major conference newsrooms (ASCO, ESMO, ASH, AACR, AHA), London Stock Exchange RNS (Investegate), and HKEX announcements.
No. This tool is for informational and research purposes only. It aggregates publicly available data and applies automated scoring. It does not constitute financial advice. Always conduct your own due diligence and consult a qualified financial advisor before making investment decisions.
Yes. The dashboard includes an Export CSV button that downloads the currently filtered view as a CSV file, ready for import into Excel, Google Sheets, or your analysis tool of choice.
Healthcare Discovery Monitor is a specialized tool within the StrategyLand Research Center ecosystem. While StrategyLand's stock screener provides quantitative 7-factor analysis across markets, this monitor focuses specifically on real-time healthcare event intelligence - complementing your screening with timely regulatory and clinical trial data.